INTRODUCTION
Non-Hodgkin lymphomas (NHLs) are considered an AIDS-defining condition and currently represent the most common types of cancer in individuals with HIV infection in developed countries. Kaposi's sarcoma used to be more common than NHL, and although it remains more common in sub-Saharan Africa, Kaposi's sarcoma has decreased in incidence in the developed countries, so that NHL now has a higher incidence than Kaposi's sarcoma in this part of the world [1, 2] . One recent epidemiologic study found that NHL comprises 53% of all AIDSdefining cancers [1] . Furthermore, NHLs have been reported to be the most common cancer-related cause of death in HIV-infected individuals in the USA (36% of deaths during 1996-2006) [1] . Whereas NHL overall has been decreasing in incidence since the introduction of combined antiretroviral therapy (cART), classical Hodgkin lymphoma (CHL) has been increasing in incidence. Although in the USA, CHL appears to remain much less commonly reported in HIV-infected patients than NHL [2] , the Swiss Cohort Study found a Standardized Incidence Ratio (SIR) of 35 for CHL, which was higher than that of Kaposi's sarcoma (SIR ¼ 25) and NHL (SIR ¼ 24) [3] . Here, we will review the pathology of AIDS-related lymphomas, including NHL and CHL, providing the most up-to-date nomenclature and pathologic diagnostic criteria.
The pathogenesis of NHL in the context of AIDS is complex and may be related to disrupted immune surveillance, viral infection, genetic alterations, chronic antigenic stimulation, and cytokine dysregulation [4] [5] [6] . In terms of viral infection, the effects of HIV may be indirect, by altering the immune responses, but possible direct effects through secreted viral proteins have not been ruled out [7 & ]. What is clear is that specific lymphoma subtypes are caused by one or both herpesviruses of the gamma subfamily: Epstein-Barr virus (EBV/ HHV-4) and Kaposi's sarcoma herpesvirus (KSHV/ HHV-8). Although it has been difficult to pinpoint the specific immunological events that lead to lymphoma, several B-cell stimulatory cytokines have been found to be increased in HIV-infected people prior to a diagnosis of lymphoma, in particular IL-6, IL-10, CRP, sCD23, sCD27, and sCD30 [8] .
One recent study revealed that the serum levels of the CXCL13 chemokine are increased in HIV-infected individuals before a diagnosis of lymphoma and furthermore, specific alleles of CXCL13 or its receptor CXCR5 are associated with these increased CXCL13 levels, suggesting a possible genetic predisposition [9 && ]. Assessment of the serum levels of these cytokines may be used to identify patients at highest risk for NHL, and perhaps for earlier diagnosis.
LYMPHOMA SUBTYPES OCCURRING IN HIV-INFECTED INDIVIDUALS
AIDS-related lymphomas are almost always of B-cell origin and some distinct lymphoma types are more common. Some of these lymphoma types can occur in both HIV uninfected and infected patients, whereas others preferentially develop in the context of HIV or in patients with other immunodeficiencies. The latter tend to be more frequently viral associated. HIV-related lymphomas have traditionally been classified by morphology and by primary site of presentation (i.e. systemic, primary central nervous system, and body cavity) [6] . More recently, these lymphomas have been classified according to the WHO classification as distinct disease entities based on morphology, immunophenotype, and, in some instances, molecular alterations [10, 11] . The distribution of these subtypes and association with EBV, as determined on analysis of 72 cases is shown in Fig. 1a .
Diffuse large B-cell lymphomas
These lymphomas occur in both HIV infected and uninfected individuals, but there are some differences between these two groups. In the context of HIV, diffuse large B-cell lymphomas (DLBCLs) have been divided on the basis of cellular morphology into centroblastic and immunoblastic categories. The immunoblastic type is mostly seen in people with AIDS, and is more frequently associated with EBV infection, with reported rates approaching 90%. EBV is most commonly detected in diagnostic pathology laboratories using in-situ hybridization for EBV-encoded RNAs (Fig. 1b) , which are abundantly expressed, noncoding viral RNAs. Patients with the immunoblastic variant usually have very advanced AIDS and are significantly immunosuppressed, so the frequency of this subtype has dramatically decreased with the widespread use of cART in the USA and Europe. The reason why these lymphomas occur in people with more advanced immunodeficiency is that EBV within the tumor cells expresses a number of proteins, including LMP1 and EBNA2, that are oncogenic but also immunogenic, in what has been termed a Latency III pattern (reviewed in [12] ). In contrast, cases with centroblastic morphology occur in individuals with or without AIDS, and these are further subdivided into germinal center and nongerminal center subtypes in both patient populations. However, in people with AIDS, the clinical significance of this subclassification remains controversial and may be treatment dependent [13] [14] [15] . Differences in DLBCLs occurring in HIVpositive patients when compared to DLBCL occurring in immunocompetent individuals include more frequent extranodal presentation, a larger proportion of the germinal center subtype, and a more common association with EBV in HIV (30% vs. <5%). One recent study of 70 AIDS-related DLBCL showed that EBV positivity was independently associated with a higher 2-year overall mortality and recommended incorporating EBV status with IPI in prognostic categorization [16 & ], although this association has not been found in other studies [13] .
A diagnosis of DLBCL can be made from biopsies based on a loss of normal tissue architecture, with infiltration of large B cells. B-cell origin should be confirmed by immunohistochemistry for a B-cell antigen, such as PAX5 or CD20. For classification into subtypes by cell of origin, molecular approaches such as gene-expression profiling are more reliable; however, as this is not always available as part of routine diagnosis, surrogate immunohistochemistry can be used, as illustrated in Fig. 2 [17] . In the context of a lymphoma occurring in the setting of HIV, immunohistochemistry with Ki67 is also useful to evaluate the proliferation index, which can have prognostic significance; individuals with tumors with higher proliferation
KEY POINTS
Individuals with HIV infection are at increased risk of lymphoma development.
Certain lymphoma subtypes are more common in people with AIDS.
Lymphomas in HIV-infected individuals are most frequently of B-cell origin.
The association with EBV or KSHV is much more common in HIV than in the general population.
Hodgkin lymphoma appears to be increasing in incidence in people with HIV.
Few genomic studies have been conducted specifically on AIDS-related lymphomas, and much of our current understanding comes from studies in lymphomas in the general population.
appear to respond better to chemotherapy [13] . In addition, although many DLBCLs can have very high proliferation rates, in some instances Ki67 may help differentiate a DLBCL from a Burkitt's lymphoma. Primary central nervous system (CNS) lymphoma is a subtype of DLBCL that is much more common in HIV-infected individuals and is very similar to the immunoblastic variant. Tumor cells have an immunoblastic morphology, frequent EBV infection, and it has declined in incidence with cART.
Burkitt's lymphomas
This is another lymphoma type that can be present in people with or without HIV infection. Three epidemiologic subtypes are recognized (endemic, sporadic, and AIDS related). Burkitt's lymphomas account for around 14% of AIDS-related NHL and is more commonly seen with HIV infection than with other forms of immunodeficiency such as transplant recipients [12, 18] . This disease typically occurs in less immunosuppressed patients with HIV, peaking at CD4 lymphocyte counts above the laboratory cutoff for AIDS onset (200 cells/ml) [19] . In HIVinfected patients, Burkitt's lymphomas may have the typical histologic features of Burkitt's lymphomas, which are characterized by cohesive sheets of malignant cells that are small-to-intermediate sized and contain moderately abundant basophilic cytoplasm and round, regular nuclei possessing two to five distinct nucleoli. Classical pathologic features of Burkitt's lymphoma are the presence of abundant mitotic figures and numerous, evenly distributed tingible body macrophages with abundant clear cytoplasm that lead to a starry-sky pattern ( Fig. 3 ). However, individuals with HIV can also have Burkitt's lymphoma with atypical features, such as some showing plasmacytoid differentiation and others exhibiting greater nuclear polymorphism. In the past, these cases were referred to as atypical Burkitt's or Burkitt-like lymphoma, but these categories are no longer favored and a separate category has been described, called B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt's lymphomas [10] . Immunohistochemically, Burkitt's lymphoma is characterized by positivity for B-cell antigens, CD10, and BCL6, and negativity or only weak positivity for BCL2. Importantly, Burkitt's lymphoma is one of the fastest growing tumors in humans, which can be shown with Ki67 immunohistochemistry that will stain practically all the tumor cells.
Translocation of MYC into one of the immunoglobulin loci is the molecular hallmark of Burkitt's lymphoma. The most common translocation is t(8;14), involving the MYC and immunoglobulin heavy chain (IGH) genes, but in 10% of the cases it can involve MYC and one of the immunoglobulin light-chain genes. The method most commonly used to demonstrate this translocation in the clinical setting is fluorescent in-situ hybridization (FISH) using a break-apart probe, which will show a split signal regardless of the translocation partner. This translocation leads to deregulated expression of MYC. Although in rare cases, this translocation cannot be demonstrated by FISH, it is likely that MYC is nevertheless deregulated in true Burkitt's lymphoma. Mutations in the MYC regulatory and coding regions also occur in Burkitt's lymphoma [20] [21] [22] [23] [24] , and may also lead to abnormal expression or prolonged protein stability. If no demonstrable MYC translocation is identified, the histology and phenotype must be otherwise completely typical for a diagnosis of Burkitt's lymphoma.
B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt's lymphoma
The designation of B-cell lymphoma, unclassifiable (BCL-U), with features intermediate between DLBCL
AIDS-related Burkitt lymphoma
Immunophenotype: CD20/Pax5 + CD10 + BCL6 + BCL2 -or weak Ki67 >95% and Burkitt's lymphoma, has been given to highgrade lymphomas that do not fit cleanly into the DLBCL or Burkitt's lymphoma categories [25] . Previously, some of these cases were classified as atypical or Burkitt-like lymphoma. The presence of or absence of MYC translocations is not sufficient to place into this category the otherwise typical cases of Burkitt's lymphoma or DLBCL, respectively. This category is rather confined to cases with an unusual morphology or phenotype. BCL-U appears to be a heterogeneous category, but is useful for classification purposes. Some of these may belong to a separate molecular category ascribed to lymphomas with MYC translocations with a complex karyotype, with additional translocations in oncogenes such as BCL-6 and BCL-2. Some of these cases may correspond to those cases classified by histology as Burkitt's lymphoma, but upon geneexpression profiling they do not have a Burkitt signature [26, 27] . These cases include both EBV positive and negative cases, but the proportion is not clear.
Classical Hodgkin's lymphoma
Although not considered an AIDS-defining malignancy, CHL is increased in incidence in HIV-infected individuals [28] , and the proportion of CHL appears to have increased in patients with longer survival and better immunological status [28] . This disease occurs in both HIV infected and uninfected individuals; however, there are some differences in these two patient populations. One of these differences is the association with EBV; approximately one-third of CHLs are positive for EBV in immunocompetent individuals, but almost all cases are positive for EBV in HIV-infected patients. In addition, although the nodular sclerosis subtype is more common in the general population, the mixed cellularity or lymphocyte-depleted forms of CHL comprise the vast majority of cases in HIV-positive patients [10, 29] .
Primary effusion lymphoma
This lymphoma subtype occurs primarily, albeit not exclusively, in HIV-infected individuals. The presence of KSHV within the tumor cells is a diagnostic criterion for this disease, and a vast majority also contain EBV [10, 30, 31 ]. Case reports have described patients presenting with a primary lymphomatous effusion that lack KSHV, but this appears to be a different disease entity, which has been called KSHV-negative or HHV-8-negative primary effusion lymphoma (PEL) [32] [33] [34] [35] . A recent report of two cases and review of the literature describes 48 cases of KSHV-negative PEL, with 21% being positive for EBV and 22% for the hepatitis C virus (HCV). Remarkably, when clinical information was available, all these KSHV-negative cases occurred in HIV-negative individuals and had a median age at diagnosis of 74 years [36 & ], highlighting that this is a disease that is different than PEL. Classical PEL is characterized, in addition to KSHV infection, by the lack of expression of B-cell-associated antigens and immunoglobulins, in spite of being a lymphoma of B-cell origin based on the presence of monoclonal immunoglobulin gene rearrangements. This lack of B-cell antigens in a neoplastic cell of B-cell origin is reminiscent of the Reed-Sternberg cells of CHL. Diagnostically, the tumors cells are large, with features that can be immunoblastic or anaplastic, but immunophenotypically are difficult to classify. They do express CD138, which is an antigen present in differentiated B cells, such as plasma cells and multiple myeloma. The presence of KSHV is most easily documented by immunohistochemistry for the KSHV nuclear antigen LANA (encoded by ORF73), which is commercially available.
PEL is a rare disease, accounting for less than 5% of all HIV-related NHLs. The most common presentation is an effusion involving one or more of the pleural, peritoneal, and pericardial spaces. However, about one-third of the cases can show dissemination to extracavitary sites. In addition to classical PEL, KSHV can be found in the tumor cells of some rare cases of AIDS-related NHL with no evidence of body cavity involvement. These have been called solid or extracavitary PEL. These represent approximately 5% of all AIDS-NHLs and they typically have the morphology of immunoblastic lymphoma; but like PELs, they frequently lack expression of B-cell antigens and are commonly coinfected with EBV [37] .
Plasmablastic lymphoma
This aggressive malignancy was first reported in the oral cavity of HIV-infected individuals [38] , but can also occur in other sites, as well as in conjunction with other immunodeficient states [39] . There may be an uneven geographic distribution, as this lymphoma subtype seems to be particularly common in HIV-infected patients in India [40] . The vast majority of cases in the oral cavity are EBV infected, but in other sites, EBV can be found in around 75% of cases. The immunophenotype is that of plasma cells. There is expression of plasma cell antigens like MUM1 and CD138, but usually no expression of B-cell antigens like CD20 and CD79a. In contrast to the immunophenotype seen in PEL, there is expression of monotypic cytoplasmic immunoglobulin in the majority of cases. The stringency of the criteria used for classification of PBL has varied over time, leading some studies to use a very strict definition (including presentation in the oral cavity and presence of EBV) which has resulted in this tumor being considered extremely rare [38] , to a more general definition provided by the WHO that accepts EBV-negative cases and extraoral presentation, as long as the morphology and immunophenotype are that of B immunoblasts or plasma cells [41] . A recent report of five cases with a review of the literature identified 248 PBL cases, out of which 157 were in HIV-positive patients, 43% were outside the oral cavity, and EBV was identified in 86% [42] . This is a highly aggressive tumor with a median survival of around 14 months. Approximately half of the cases have been shown to have a MYC translocation [43] . This study failed to detect rearrangements of other oncogenes altered in lymphoma (BCL2, BCL6, MALT1, and PAX5), but gains in these loci were found in over a third of the cases.
Lymphoma arising in Kaposi's sarcoma herpesvirus-associated multicentric Castleman's disease
These lymphomas mainly occur in HIV-positive patients [44] and are very rare. They were initially called plasmablastic lymphomas (PBLs) [44] . However, they are different from PBLs (described above) in that they are KSHV positive, but EBV negative. Lymphomas arising in KSHV-associated multicentric Castleman's disease (MCD) are also different from PEL in that they are EBV negative and express IgMl cytoplasmic immunoglobulin (whereas PELs do not express immunoglobulin). These lymphomas do not contain mutations in the immunoglobulin genes and are thought to arise from naïve B-cells rather than terminally differentiated B-cells as in PEL. A different entity has also been reported, called germinotropic lymphoproliferative disorder, in which germinal center B-cells are coinfected with EBV and KSHV [45] .
Polymorphic B-cell lymphomas
These are rare lesions, but morphologically resemble polymorphic post-transplantation lymphoproliferative disorders (PTLDs) [46] .
MOLECULAR ANALYSIS OF AIDS-RELATED LYMPHOMAS AND DIAGNOSTIC IMPLICATIONS
Genetic alterations can be useful for the proper classification of different lymphoma subtypes. For example, FISH is routinely used to detect MYC, BCL2, and BCL6 translocations to support a diagnosis of Burkitt's lymphoma, follicular lymphoma, and DLBCL, respectively. Therefore, gaining additional understanding of what defines a specific diagnostic entity can assist diagnosis. With the introduction of advanced genomic approaches, we have gained a much deeper understanding of cell of origin, driving genetic alterations, and pathogenetic mechanisms of many cancers, including lymphoma. During the last year, a series of next-generation sequencing studies have been published reporting novel alterations in Burkitt's lymphoma [47
A notable finding was the presence of frequent genomic alterations in TCF3 (also called E2A) or its negative regulator ID3. TCF3 is a transcription factor that can activate the PI3K pathway, increasing tonic B-cell receptor signaling [47 && ]. Although these studies examined mostly cases obtained from immunocompetent or not otherwise specified patients, it may be assumed that many of the same alterations will be found in Burkitt's lymphoma cases occurring in people with AIDS, as this is known to be the case for major translocations that we have recognized for some time (i.e. MYC and BCL6). However, many of the newly described alterations have not yet been evaluated specifically in the context of AIDS.
Very few genomic studies have focused exclusively on AIDS-related lymphomas in the last few years. Deffenbacher et al. [51] evaluated 20 cases for gene expression and somatic DNA copy number changes by high-resolution array comparative genomic hybridization which reported numerous gain and losses, including some novel ones, reflecting great molecular heterogeneity in AIDS-related lymphomas. A more focused study recently identified genetic alterations leading to loss of function of the tumor suppressor gene A20 in 23% of AIDSrelated lymphomas [52] . A20 plays a role in inhibiting NF-kB, a transcription factor that is active and involved in cell survival of DLBCL of nongerminal center origin. The LMP1 protein encoded by EBV and expressed in a subset of AIDS DLBCLs potently activates NF-kB, adding a rationale for evaluating this pathway in the context of lymphomas with EBV infection. In AIDS-related lymphoma, A20 inactivation was found in 23% of cases, and there was no predilection for a specific histologic subtype. Both EBV positive and negative cases showed A20 inactivation, but LMP1 was usually not expressed in the EBV-positive cases with A20 abnormalities, indicating that the loss of A20 function may be an alternative mechanism of NF-kB activation in AIDS-related lymphoma cells.
CONCLUSION
We currently have a good understanding of how to classify the major types of lymphoma that occurs in HIV-positive individuals. Much of the information about the molecular alterations in these cases comes from the genomic analysis of the same tumor types occurring in the general population, but some studies have focused specifically on the analysis of AIDS-related lymphomas. One of the most significant differences in lymphomas occurring among HIV infected and uninfected individuals is a higher association with a oncogenic herpesviruses, namely EBV and KSHV. Many studies have focused over the last years in understanding the mechanisms of oncogenesis of these viruses, and assessment of their presence or absence can greatly help with accurate diagnosis and classification. It is not yet clear whether there are other, as yet unidentified, oncogenic infectious agents. Additional questions remain regarding the pathologic diagnosis of AIDS-related lymphomas. In particular, two entities, PBLs and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt's lymphoma, remain poorly defined with low concordance in terms of accurate diagnosis even among experienced pathologists. Some of these cases may comprise distinct clinicopathologic categories, and it is likely that next-generation sequencing and other advanced genomic tools will identify distinct molecular entities. The challenge thus far has been the limited number of patient specimens to do these analyses for rare subtypes, in particular for methods that would require fresh or frozen tissue. Nevertheless, when garnered, this information is likely to lead to a better understanding and therapies based on specific genetic alterations.
